Alpha 2.0
Login Register
» Authors » P A Fasching

P A Fasching

Explore the profile of P A Fasching including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 104
Citations 2744
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
General Surgery
Top 10 Co-Authors
M W Beckmann
M P Lux
R Schulz-Wendtland
C Rauh
T Fehm
S Loibl
M Untch
W Janni
C R Loehberg
A Schneeweiss
Published In
Geburtshilfe Frauenheilkd
Ann Oncol
Br J Cancer
Eur J Cancer
Breast
Affiliations
Soon will be listed here.
Recent Articles
1.
Efficacy of subsequent therapies in patients with advanced ovarian cancer who relapse after first-line olaparib maintenance: results of the PAOLA-1/ENGOT-ov25 trial
Harter P, Marth C, Mouret-Reynier M, Cropet C, Lorusso D, Guerra-Alia E, et al.
Ann Oncol . 2024 Nov; 36(2):185-196. PMID: 39528049
Background: The use of first-line poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy is increasing in advanced ovarian cancer. Understanding the efficacy of first subsequent therapy (FST) in patients experiencing disease progression...
2.
Prognosis prediction with the IHC3 score in patients with node-negative, hormone receptor-positive, HER2-negative early breast cancer
Seitz K, Goossens C, Huebner H, Gass P, Uhrig S, Heindl F, et al.
ESMO Open . 2024 Oct; 9(11):103963. PMID: 39461262
Background: Prognostication has been used to identify patient populations that could potentially benefit from treatment de-escalation. In patients with hormone receptor-positive (HRpos), human epidermal growth factor receptor 2-negative (HER2neg) early...
3.
A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
Hortobagyi G, Lacko A, Sohn J, Cruz F, Ruiz Borrego M, Manikhas A, et al.
Ann Oncol . 2024 Oct; 36(2):149-157. PMID: 39442617
Background: NATALEE assessed efficacy and tolerability of 3 years of adjuvant ribociclib plus a nonsteroidal aromatase inhibitor (NSAI) compared with an NSAI alone in a broad population of patients with...
4.
Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522
Pusztai L, Denkert C, OShaughnessy J, Cortes J, Dent R, McArthur H, et al.
Ann Oncol . 2024 Feb; 35(5):429-436. PMID: 38369015
Background: KEYNOTE-522 demonstrated statistically significant improvements in pathological complete response (pCR) with neoadjuvant pembrolizumab plus chemotherapy and event-free survival (EFS) with neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab in...
5.
Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant
Neven P, Fasching P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al.
Breast Cancer Res . 2023 Aug; 25(1):103. PMID: 37653397
Background: The phase III MONALEESA-3 trial included first- (1L) and second-line (2L) patients and demonstrated a significant overall survival (OS) benefit for ribociclib + fulvestrant in patients with hormone receptor-positive,...
6.
Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2- metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized...
Harbeck N, Fasching P, Wuerstlein R, Degenhardt T, Luftner D, Kates R, et al.
Ann Oncol . 2023 May; 34(8):660-669. PMID: 37201751
Background: The multicenter, randomized, phase IV, intergroup AGO-B WSG PreCycle trial (NCT03220178) evaluated the impact of CANKADO-based electronic patient-reported outcome (ePRO) assessment on quality of life (QoL) in hormone receptor-positive,...
7.
Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study
Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, et al.
Ann Oncol . 2023 May; 34(7):569-577. PMID: 37179020
Background: In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior progression-free survival and overall survival versus trastuzumab emtansine (T-DM1) and manageable safety in patients with human epidermal growth factor...
8.
A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE)
Schmidt M, Lubbe K, Decker T, Thill M, Bauer L, Muller V, et al.
ESMO Open . 2022 Nov; 7(6):100601. PMID: 36356410
Background: Stomatitis is one of the main reasons to discontinue everolimus in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). To decrease stomatitis...
9.
Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response
Loibl S, Schneeweiss A, Huober J, Braun M, Rey J, Blohmer J, et al.
Ann Oncol . 2022 Aug; 33(11):1149-1158. PMID: 35961599
Background: Addition of immune checkpoint inhibitors to neoadjuvant chemotherapy (NACT) is a promising strategy in early breast cancer, but the optimal duration of therapy is currently unknown. In the GeparNuevo...
10.
Corrigendum to "A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study": [Annals of...
Loibl S, Untch M, Burchardi N, Huober J, Sinn B, Blohmer J, et al.
Ann Oncol . 2022 May; 33(7):743-744. PMID: 35595658
No abstract available.